Outcomes & Stories
July 13, 2026
I first heard about Biograph from a close friend who is a member of their San Francisco clinic location and she couldn’t stop talking about it: the experience, the technology, the depth of insight into her health. She described it as the most comprehensive healthcare evaluation she’d ever had.
Curious and inspired by her story, I decided to schedule my own Membership Day in 2024. At that time, I was in my mid 30s, feeling great, and living what I would define as my healthiest life. I had no symptoms, no family history, and no reason to suspect anything was wrong.
I wanted to experience Biograph’s proactive health approach firsthand; to understand how data, imaging, and personalized insights could optimize my wellbeing.
What I didn’t expect was that Biograph would save my life.
How an MRI detected my pancreatic tumor
During my first visit day, Biograph’s medical team identified a small, rare tumor on my pancreas, later diagnosed as a Solid Pseudopapillary Neoplasm (SPN).
Pancreatic cancer is often called the “silent killer” because it rarely causes symptoms until it’s far advanced. But thanks to Biograph’s preventative imaging, we caught mine early, before it spread, before symptoms, before it was too late.
Biograph immediately connected me with the Stanford University Medical Team, who confirmed the diagnosis and designed a personalized treatment plan. Within weeks, I underwent surgery to remove 25% of my pancreas, while preserving my spleen and vital organs.
Today, I’m cancer-free. The tumor is gone. The recovery was challenging, but I’m deeply grateful to Biograph, to Stanford, and to everyone who stood beside me.
What I learned after a pancreatic tumor diagnosis
This journey changed the way I think about prevention, gratitude, and the future of healthcare. These are the lessons that have stayed with me most:
Proactive Health
Early detection truly saves lives; it saved mine. My cancer was found through a preventive MRI when I had no signs or symptoms.
Gratitude
To Biograph’s dedicated team for the early detection, to my colleagues at OpenAI for their support, to my husband, family, and community for surrounding me with strength.
Hope for the Future
I’m inspired by the incredible potential of AI in healthcare. With platforms like Biograph, early detection and precision treatment are becoming more accessible, and I’m excited to champion that change.
Why early detection matters for pancreatic cancer
Traditional medicine waits for symptoms. For pancreatic cancer, that is a failing strategy. Its reputation as a "silent killer" is well-earned, as it rarely causes symptoms until it has grown and spread. As a result, an estimated 80-85% of patients are diagnosed at locally advanced or metastatic stages, when curative surgery is no longer an option [1]. This grim reality is why pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2030 [2].
Maggie's discovery stands in stark contrast to this trend. She was completely asymptomatic, fitting the profile of a patient who would have been missed by the traditional healthcare system. Standard guidelines do not recommend screening for pancreatic cancer in the general, asymptomatic population, as the disease's low prevalence can lead to high false-positive rates [3]. Her story demonstrates the profound value of an individualized, proactive approach for those who want to go beyond the standard of care.
The Biograph Method: Integrating data for early detection
Detecting silent risks requires a system that looks beyond symptoms. Biograph's framework is designed to do exactly this, combining advanced diagnostics to build a comprehensive, multi-dimensional picture of an individual's health. We reject the limitations of reactive medicine. We empower our members with the data they need to act early.
Maggie's discovery was enabled by advanced imaging. The whole-body MRI provides a non-invasive anatomical survey capable of identifying abnormalities like tumors long before they produce symptoms. While a whole-body MRI is a powerful initial detection tool, our approach goes further, integrating multiple data streams to identify risk even before a physical lesion is visible [7].
Family History
Individuals with close relatives who have been diagnosed with pancreatic cancer, particularly at younger ages, may have a significantly elevated lifetime risk. By incorporating detailed family history into our assessment, we can identify members who may benefit from additional surveillance, genetic testing, or a more personalized prevention strategy.
Multi Cancer Early Detection Test
This blood-based screening detects more than 50 types of cancer, many of which are not commonly screened for today. With a simple blood draw, this test provides early detection insights that can help you be proactive about your health, looking at the DNA in your blood to determine if any of it may have come from cancer cells. The results can also point to where in the body the cancer is coming from.
Genetic Screening
Hereditary factors play a role in 5-10% of pancreatic cancers [8]. Our genomic analysis screens for germline mutations in genes like BRCA1, BRCA2, and PALB2 among others that confer an increased lifetime risk, allowing for tailored surveillance strategies.
Longitudinal Biomarker Tracking
We establish a personalized health baseline and track hundreds of biomarkers over time. Subtle deviations in metabolic or inflammatory markers can signal underlying dysfunction years before a disease like cancer develops.
Comprehensive Data Integration
By integrating imaging, genomics, and deep biomarker analysis, we can identify individuals at elevated risk who may warrant closer surveillance. This is how we create opportunities for curative intervention.
What this story teaches us about preventive health
Maggie's story is a powerful reminder that "feeling healthy" isn't a guarantee of being healthy. For a disease like pancreatic cancer, which will affect approximately 1 in 60 women in their lifetime, her journey from asymptomatic to survivor is a lesson for everyone [9]. By choosing to look deeper into her health, Maggie transformed a silent, life-threatening diagnosis into a story of empowerment.
The single most important lesson from her experience is that you cannot wait for symptoms to take charge of your health. When it comes to silent diseases, waiting for a warning sign means you have already lost your most valuable asset: time. Proactive, comprehensive screening is the most powerful tool available to change your future health.
Her journey proves that you have the power to move beyond the limitations of reactive healthcare. You can own your health data and find answers before there are even questions. The future of medicine is one where stories like Maggie's become the norm, not the exception-a future powered by advanced diagnostics, data-driven insights, and a proactive mindset.
Commonly asked questions about pancreatic cancer and early detection
Can pancreatic cancer be detected before symptoms appear?
In some cases, yes. Pancreatic cancer is often called a “silent killer” because it rarely causes symptoms until it has progressed to a more advanced stage. Advanced imaging and other preventive health assessments may occasionally identify abnormalities before symptoms develop, creating opportunities for earlier evaluation and treatment.
What is a Solid Pseudopapillary Neoplasm (SPN)?
A Solid Pseudopapillary Neoplasm (SPN) is a rare type of pancreatic tumor that most commonly affects younger women. While many SPNs are slow-growing, they can become malignant. When detected early and surgically removed, outcomes are generally very favorable.
Can a whole-body MRI detect pancreatic tumors?
A whole-body MRI can identify structural abnormalities throughout the body, including the pancreas. While it is not designed specifically as a pancreatic cancer screening test, advanced imaging may occasionally detect tumors or other abnormalities before symptoms develop.
What are the early symptoms of pancreatic cancer?
Early-stage pancreatic cancer often causes no symptoms at all. When symptoms do occur, they may include abdominal pain, back pain, unexplained weight loss, jaundice, digestive changes, or new-onset diabetes. Unfortunately, these symptoms often appear after the disease has already progressed.
Why is pancreatic cancer called the “silent killer”?
Pancreatic cancer is often referred to as a “silent killer” because it can grow and spread for months or years before causing noticeable symptoms. As a result, many patients are diagnosed at later stages when treatment options are more limited.
How does Biograph identify health risks before symptoms develop?
Biograph uses a comprehensive preventive health approach that combines advanced imaging, blood biomarkers, genetic analysis, functional testing, and physician-led interpretation. By integrating multiple sources of health data, Biograph aims to identify potential risks earlier and provide members with personalized recommendations.
What happens after an abnormal finding on a preventive MRI?
If an abnormality is identified, Biograph’s medical team reviews the findings and coordinates appropriate follow-up care. Depending on the nature of the finding, this may include additional imaging, specialist consultations, diagnostic testing, or referrals to leading medical centers for further evaluation and treatment.
Who should consider advanced preventive health screening?
Advanced preventive health screening may be appropriate for individuals who want a deeper understanding of their health than is typically provided through routine medical care. Many people seek preventive screening to better understand their risk for conditions such as cardiovascular disease, cancer, metabolic dysfunction, and neurodegenerative disease before symptoms develop.
Maggie Hott
GMT Leader at OpenAI
Maggie Hott leads go-to-market strategy at OpenAI, where she oversees the company's global expansion and enterprise adoption initiatives. With over a decade of experience in scaling AI-first companies, she has been instrumental in OpenAI's growth from startup to industry leader. She joined Biograph in 2024.
Clinical references
Golan, T., & Ueno, H. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Clinical Cancer Research. 2022;28(19):4179-4181. doi:10.1158/1078-0432.CCR-22-1234.
Cohen D. Pancreatic Cancer: Current Challenges, Future Directions – Can we make the Impossible...Possible? [Grand Rounds]. Icahn School of Medicine at Mount Sinai; 2021.
Singhi, A. D., et al. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Cancer Prevention Research. 2019;12(11):727-734. doi:10.1158/1940-6207.CAPR-19-0128.
Pancreatic Cancer Action Network. Pancreatic Cancer Survival Rate. Pancreatic Cancer Action Network. 2025.
Fishman, E. K., et al. SPEN Tumors of the Pancreas 2021: What You Need to Know - Part 1. CTisus. [Video]. 2021. & Reiss, P., et al. Outcome and prognosis after pancreatectomy in patients with solid pseudopapillary neoplasms. Pancreatology. 2019;19(6):859-865. doi:10.1016/j.pan.2019.06.008.
Zhang, H., et al. Long-term Survival, Quality of Life, and Molecular Features of the Patients With Solid Pseudopapillary Neoplasm of the Pancreas: A Retrospective Study of 454 Cases. Annals of Surgery. 2023;278(5):e1053-e1061. doi:10.1097/SLA.0000000000005842.
Kovacevic, B., et al. Challenges of early detection of pancreatic cancer. JCI Insight. 2025;10(20):e185392. doi:10.1172/jci.insight.185392.
Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018;24(19):2047-2060. doi:10.3748/wjg.v24.i19.2047.
American Cancer Society. Key Statistics for Pancreatic Cancer. cancer.org. January 16, 2025.
